Dr Joel Spero stated that a major effort was necessary to develop a 'clean' product rapidly, in order to treat the next generation of haemophilia patients. Read more about Dr Joel Spero stated that a major effort was necessary to develop a 'clean' product rapidly, in order to treat the next generation of haemophilia patients.
PFC Liberton first issued Factor 8 from plasma tested for HIV/HTLV-3 antibody in February 1986. Read more about PFC Liberton first issued Factor 8 from plasma tested for HIV/HTLV-3 antibody in February 1986.
Scotland produced DEFIX and similarly to BPL/PFL's 9A product, there were worries It could lead to thrombosis in some cases. Read more about Scotland produced DEFIX and similarly to BPL/PFL's 9A product, there were worries It could lead to thrombosis in some cases.
Dr Foster stated that observations confirmed that Factor 8 activity could be destroyed even by modest increases in temperature, and at the time it seemed inconceivable that Factor 8 could be heat treated at a temperature high enough to eliminate the risk of hepatitis transition. Read more about Dr Foster stated that observations confirmed that Factor 8 activity could be destroyed even by modest increases in temperature, and at the time it seemed inconceivable that Factor 8 could be heat treated at a temperature high enough to eliminate the risk of hepatitis transition.
PFC routinely issued heat-treated Factor 9 from August 1985. Read more about PFC routinely issued heat-treated Factor 9 from August 1985.
The CBLA agreed to finance the trial of 8CRV. Read more about The CBLA agreed to finance the trial of 8CRV.
A survey published in the "British Medical Journal" showed that a fifth of centres were using heat treated commercial Factor 9. Read more about A survey published in the "British Medical Journal" showed that a fifth of centres were using heat treated commercial Factor 9.
Preliminary results on the heat treatment of PFC Factor 8 concentrate were published. Read more about Preliminary results on the heat treatment of PFC Factor 8 concentrate were published.
In March 1984, BPL products made by combining a "small pool" approach and heat treatment were used for the first time. Read more about In March 1984, BPL products made by combining a "small pool" approach and heat treatment were used for the first time.
Peter Jones wrote to Medical Assessor, The Committee on Safety of Medicines urging that any material that had not been collected in low risk areas, been individually donor tested and heat treated in an approved manner, should be withheld, at the very least from seronegative people. Read more about Peter Jones wrote to Medical Assessor, The Committee on Safety of Medicines urging that any material that had not been collected in low risk areas, been individually donor tested and heat treated in an approved manner, should be withheld, at the very least from seronegative people.